The American Academy of Pediatrics is splitting from the federal government in its recommendations on which children should ...

Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in ...

A new study shows that while RSV mostly affects younger kids, the often-overlooked human metapneumovirus also hospitalizes ...

Merck MRK stock has declined 4% since it announced second-quarter results on July 29 before market open. While the company’s ...

Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery.

Merck KGaA, the German science and technology group, lowered its full-year sales growth forecast as it grapples with a weaker dollar and a slowdown in its electronics business.

The group lifted its full-year guidance for growth in underlying earnings, due to better prospects for its life-sciences and healthcare segments, but was cautious on sales.

Pregnant individuals commonly reported hesitancy toward RSVpreF and nirsevimab, indicating the need for efforts to promote the safety and uptake of RSV immunization.

Moderna faces weak post-pandemic vaccine demand and financial struggles, with limited near-term catalysts. Click here to read an analysis of MRNA stock now.

July Layoffs: Sarepta, Moderna Cut Hundreds While Merck had the largest projected layoffs, other companies also made significant cuts, with Sarepta Therapeutics grabbing the biggest headlines.

We have made great progress in achieving the milestones necessary to help ensure a successful launch and are well-positioned to help protect infants from RSV lower respiratory tract disease.